[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Cell Therapy Group Co.,Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":200},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,74,98,121,146,166,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100629822","phase-1-an-antibody-armored-dendritic-cell-in-patients-with-solid-tumors-100629822",false,"NCT07479667","An Antibody-armored Dendritic Cell in Patients With Solid Tumors","An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors","dendritic cell","Inclusion Criteria:\n\n* Aged 18 to 80 years, body weight ≥ 40 kg; male or female, no gender restriction;\n* ECOG performance status score of 0 to 1;\n* Histopathologically confirmed solid tumors including pancreatic cancer, colorectal cancer (CRC), gastric cancer and other such malignancies;\n* Having undergone R0 or R1 resection with completion of at least 4 cycles of standard postoperative adjuvant chemotherapy;\n* Positive expression for at least one of TERT, P53, KRAS and Survivin;\n* Sufficient venous access with no contraindications to peripheral blood mononuclear cell collection;\n* Adequate organ and bone marrow function:\n* a) Platelet count ≥ 90×10⁹\u002FL;\n* b) Hemoglobin ≥ 90 g\u002FL (no blood transfusion or erythropoietin dependence within 7 days);\n* c) Mononuclear cell count ≥ 1.0×10⁹\u002FL;\n* d) International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × upper limit of normal (ULN);\n* e) Serum creatinine ≤ 1.5 × upper limit of normal (ULN);\n* f) Aminotransferases (AST, ALT) ≤ 2.5 × upper limit of normal (ULN);\n* g) Total bilirubin ≤ 2 × upper limit of normal (ULN);\n* h) Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as assessed by echocardiography within 1 month prior to enrollment;\n* Able to understand the study requirements and considerations and provide informed consent to participate in the clinical study in accordance with the study requirements\n* Subjects agree to use effective contraceptive measures for at least 6 months following dendritic cell (DC) injection.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding;\n* Positive for human immunodeficiency virus (HIV) antibody or syphilis antibody; positive for hepatitis B surface antigen (HBsAg), positive for hepatitis B core antibody (anti-HBc) or hepatitis B e antibody (anti-HBe) with hepatitis B virus (HBV) DNA copy number above the lower limit of detection (LLOD) or ≥ 1000 copies\u002FmL; or hepatitis C virus (HCV) RNA copy number above the LLOD;\n* Prior treatment with any dendritic cell (DC) or other immune cell therapy;\n* History of hypersensitivity to immunotherapy and related drugs, or history of severe allergic reactions;\n* Uncontrolled active infection;\n* Subjects with active autoimmune disease receiving relevant treatment; subjects with organ transplantation who are still on immunosuppressive agents; or subjects requiring long-term use of immunosuppressive agents (\\> 15 mg\u002Fday prednisone or equivalent glucocorticoid dose) and who have used them within 4 weeks prior to screening;\n* Presence of central nervous system (CNS) metastases and clinically significant CNS diseases;\n* Received systemic anti-tumor therapy within 4 weeks prior to screening;\n* Presence of residual lesions or unremoved foci on screening examinations (post-adjuvant chemotherapy \u002F post-surgery), with imaging indicating local recurrence or confirmed distant metastasis;\n* History of other active malignancies within 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.);\n* Clinically significant major cardiovascular diseases including:\n* a) Symptomatic congestive heart failure\n* b) Unstable angina pectoris\n* c) Severe arrhythmia requiring pharmacotherapy\n* d) Uncontrolled hypertension\n* e) Myocardial infarction or ventricular arrhythmia within 6 months prior to screening;\n* Any other conditions deemed by the investigator to render the subject ineligible for participation in the clinical study","ALL","18 Years","80 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is a single-arm, open-label, single-administration dose-escalation study.",[27,28],"Solid Cancers","Adjuvant Therapy","RECRUITING","2026-03-15",{"date":32,"type":33},"2026-03-18","ACTUAL",{"date":35,"type":33},"2026-02-05",{"date":37,"type":21},"2029-06-30",{"name":39,"class":40},"Shanghai Cell Therapy Group Co.,Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100606383","early-phase-1-an-exploratory-study-of-cd19cd22bcma-car-t-cells-bze2204-in-subjects-with-relapsed-or-refractory-autoimmune-diseases-100606383","NCT07174843","An Exploratory Study of CD19\u002FCD22\u002FBCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases","An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19\u002FCD22\u002FBCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases","Major Inclusion Criteria:\n\n1. Males or females, aged 18-70 years old\n2. Adequate bone marrow, hepatic, renal, coagulation and pulmonary function defined as:\n\n   * Bone marrow reservation: absolute neutrophil count (ANC) ≥1 ×10\\^9\u002FL; absolute lymphocyte count (ALC)≥ 0.5 ×10\\^9\u002FL; hemoglobulin ≥80 g\u002FL; platelets ≥50 ×10\\^9\u002FL(except for ITP);\n   * Hepatic function: i: Serum alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) ≤ 5 upper limit of normal(ULN) (except for elevations are evaluated to be related to autoimmune disease by investigators)and ii: total bilirubin ≤ 2 ULN, (except for Gilbert's syndrome patients, those with total bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN can be enrolled).\n   * Renal function: serum creatinine ≤ 1.5 ULN , or estimated glomerular filtration rate(eGFR) ≥ 60 mL\u002Fmin\u002F1.73m2 \\[eGFR=186×age\\^-0.203×SCr\\^-1.154（mg\u002Fdl）,female×0.742\\]\n   * Coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN\n   * Pulmonary function: Have the minimum level of pulmonary reserve, defined as ≤ CTCAE (Common Terminology Criteria for Adverse Events) grade 1 dyspnea and the SaO2(oxygen saturation)≥ 91% on room air\n3. Life expectancy \\> 6 months\n4. Subjects with relapsed or refractory active IIM also need meet following criteria:\n\n   * Subjects with suspected or confirmed dermatomyositis(DM), polymyositis(PM), anti-synthetase syndrome(ASS) and immune-mediated necrotizing myopathy(IMNM, need to be assessed by the investigator that the patient has no safety instability) based on the 2017 European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) classification criteria\n   * Positive (+ or above) for at least one myositis-specific antibody (MSA) or myositis-associated antibody (MAA), including anti-TIF-1γ, NXP-2, Mi-2α, Mi-2β, MDA-5, SAE-1\u002F2, SRP, HMGCR, Jo-1, PL-7, PL-12, HA, EJ, OJ, KS, Zo, Tyr, PM-Scl100, PM-Scl75, SSA\u002FRo-52, SSB\u002FLA, Ku, RNA-PIII, cN1A, etc\n   * At screening, the subject must have moderate to severe IIM, defined as manual muscle testing (MMT) ≤ 141 and 2 of the following criteria are met; or CT suggests active interstitial lung disease(ILD)\n\n     1. Physician global activity assessment (PGA) ≥ 2 cm (Visual analogue scale VAS 10 cm);\n     2. Patient global activity assessment (PtGA) ≥ 2 cm ( VAS 10 cm scale);\n     3. Extramuscular global assessment (Myositis Disease Activity Assessment Tool \\[MDAAT\\]) ≥ 2.0 cm (VAS 10 cm scale);\n     4. Health assessment questionnaire (HAQ) \\> 0.25;\n     5. Elevation in one or more muscle enzymes (CK, LDH, AST, ALT) is ≥ 1.5 ULN;\n   * Lack of efficacy or intolerance to corticosteroids and at least 1 immunosuppressant or biologic agents\n5. Subjects with relapsed or refractory active ITP also need meet following criteria\n\n   * Diagnosed with ITP for more than 3 months, including primary ITP and ITP secondary to autoimmune diseases\n   * Platelets \\\u003C50 ×10\\^9\u002FL with at least twice tests(≥24h interval)\n   * At least one platelet glycoprotein specific autoantibody positive\n   * Lack of efficacy for first line of therapy, or lack of efficacy\u002Frelapse post splenectomy\n6. Subjects with relapsed or refractory active SLE also need meet following criteria\n\n   * Diagnosed with SLE according to the 2019 EULAR\u002FACR classification criteria for at least 6 months\n   * Positive autoantibodies: antinuclear antibody (ANA) and\u002For anti-double strand-DNA(dsDNA) antibody and\u002For anti-Smith(Sm) antibody\n   * SLEDAI-2K scores ≥8 at screening. If the scores for low complement and\u002For anti-ds-DNA antibody are available, the SLEDAI-2K scores for clinical symptoms (except low complement and\u002For anti-ds-DNA antibody) should be ≥6\n   * Proliferative class III or IV , or class III+V or IV+V lupus nephritis(LN) confirmed by biopsies within 12 months; urine protein \\> 1.0g\u002F24h or urine protein creatinine ratio (UPCR) \\>1000mg\u002Fg and PGA\\>1\n   * Lack of efficacy or intolerance to at least one immunosuppressant and\u002For one biologic in medical history; for LN patients, relapse during maintenance post induction therapy is also eligible.\n\nMajor Exclusion Criteria:\n\n1. A history of severe hypersensitivity or allergic reactions, or contraindications or hypersensitivity to any component of the investigational drug\n2. Presence of any serious heart diseases defined in the protocol\n3. A medical history of severe central nervous system or symptoms within 6 months\n4. Any concurrent malignancy or a history of malignancy with exceptions indicated in the protocol\n5. Clinically significant hemorrhage symptoms or definite bleeding tendencies (except for events caused by ITP) within 6 months prior to screening; arteriovenous thrombosis events within 6 months prior to screening\n6. Any positive results of contagious diseases as following:\n\n   * Human immunodeficiency virus (HIV) antibody positive;\n   * HBsAg positive; or HBcAb\u002FHBeAb positive (subjects with HBV DNA copy numbers below the lower limit of detection can be enrolled);\n   * hepatitis C antibody (HCV-Ab) positive (the subjects with HCV RNA below the lower limit of detection can be enrolled) or a known medical history of hepatitis C;\n   * Treponema pallidum antibody (TP-Ab) positive\n   * Epstein-Barr virus(EBV), cytomegalovirus(CMV) antibody positive and copy number is above the limit\n7. Active tuberculosis or latent tuberculosis that has not been adequately treated\n8. Evidenced viral, bacterial or fungal infection that is uncontrolled or requires systemic antimicrobial therapy\n9. Requirements of wash-out period for specific treatment are not met(detailed in protocol)\n10. Subjects with relapsed or refractory active IIM will be excluded in the following situations:\n\n    * Inclusion body myositis, amyopathic dermatomyositis or secondary myositis with documented medical history\n    * Severe muscle damage\n    * Uncontrolled extra muscle damage relating to PM or DM\n11. Subjects with relapsed or refractory active ITP will be excluded if platelet \\\u003C 10x10\\^9\u002FL with active bleeding or bleeding score ≥5\n12. Subjects with relapsed or refractory active SLE will be excluded if the subject has lupus crisis within 3 month, active CNS lupus, severe hemolytic anemia, severe thrombocytopenic purpura etc\n13. Any situations evaluated by investigators that may prevent the subjects from participating in the study, or may confound the study results, or participation in this study is not in the best interests of the subjects.","70 Years",{"count":51,"type":21},20,[53],"EARLY_PHASE1","This is a single arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19\u002FCD22\u002FBCMA(BZE2204) in patients with relapsed or refractory active autoimmune diseases, including idiopathic inflammatory myopathies(IIM), immune thrombocytopenia(ITP), systemic lupus erythematosus(SLE).",[56,57,58],"Idiopathic Inflammatory Myopathies(IIM)","Immune Thrombocytopenia(ITP)","Systemic Lupus Erythematosus(SLE)",[60,61,62,63,64,65],"Autoimmune diseases","SLE","IIM","ITP","CAR-T","tri-targets","2025-09-14",{"date":68,"type":33},"2025-09-16",{"date":70,"type":21},"2025-09",{"date":72,"type":21},"2027-12",{"name":39,"class":40},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100604219","phase-1-exploratory-study-of-super-dc-cell-injection-in-preventing-recurrence-after-radical-surgery-for-tumors-100604219","NCT07146672","Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","Inclusion Criteria:\n\n* Age 18-80 years old, weight ≥ 40kg; No gender limit；\n* Subjects with malignant solid tumors diagnosed by histology or cytology and undergoing radical resection surger；\n* At the beginning of the study (after surgery), there were no lesions, no local recurrence or distant metastasis on the imaging, and no brain metastasis (images within one month before enrollment can be used for screening)；\n* Subjects in the safety verification stage need to provide immunohistochemical test results with positive expression of Survivin or P53 or MUC1;\n* ECOG score 0-1 points;\n* There are sufficient venous channels and no contraindications for peripheral blood mononuclear cell collection surgery;\n* Organs and bone marrow function well:\n* a:Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% evaluated by echocardiography within one month of enrollment; The electrocardiogram is basically normal;\n* b:Platelets ≥ 90 × 10 \\^ 9\u002FL;\n* c:Hemoglobin ≥ 90g\u002FL (no blood transfusion or erythropoietin dependence within 7 days);\n* d:Total bilirubin ≤ 2 times the upper limit of normal value;\n* e:Serum creatinine ≤ 1.5 times the upper limit of normal value;\n* f:Transaminases (AST, ALT) ≤ 2.5 times the upper limit of normal value (if liver cancer is 5 times the upper limit of normal value);\n* g:International standardized ratio (INR) or prothrombin time (PT) ≤ 1.5 times the upper limit of normal value;\n* Able to understand trial requirements and matters, willing to participate in clinical research according to trial requirements\n\nExclusion Criteria:\n\n* Positive for HIV antibodies or syphilis antibodies; positive for hepatitis B surface antigen, and positive for hepatitis B core antibody or e antibody with viral DNA copy number above the detection limit or ≥1000 copies\u002Fml; or hepatitis C virus RNA copy number above the detection limit.\n* Any uncontrollable active infection, coagulation disorder, or any other major disease;\n* Pregnant or lactating women;\n* Suffering from active neuroautoimmune or inflammatory diseases, such as any of the following: inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, multiple sclerosis, Sjogren's syndrome, etc., and receiving relevant treatment; Subjects who are still using immunosuppressants for organ transplantation; Or subjects who have been using immunosuppressive drugs such as glucocorticoids for a long time cannot stop at least 4 weeks before enrollment; Severe allergic constitution;\n* Subjects with existing abnormalities in the central nervous system, such as seizures, cerebral vascular ischemia\u002Fbleeding, dementia, cerebellar diseases, or any autoimmune diseases associated with central nervous system involvement;\n* Major cardiovascular diseases with clinical significance include:",{"count":81,"type":21},12,[24,83],"PHASE2","The study is a controlled, open-label exploratory clinical trial.",[86],"Solid Tumor Cancer",[88,89],"Vaccines","Immunologic Factors","2025-08-21",{"date":92,"type":33},"2025-08-28",{"date":94,"type":33},"2025-07-31",{"date":96,"type":21},"2026-12-31",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":120,"locationsCount":41},"100550365","early-phase-1-a-dose-escalating-study-of-cd19cd22bcma-car-t-therapy-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphomanhl-100550365","NCT06446128","A Dose Escalating Study of CD19\u002FCD22\u002FBCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)","A Dose Escalating Study of CD19\u002FCD22\u002FBCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)","Key Inclusion Criteria:\n\n* Patients who are diagnosed with relapsed\u002Frefractory B cell non-Hodgkin lymphoma , especially\n\n  * Diffuse Large B Cell Lymphoma, not other specified (DLBCL,NOS),\n  * Primary Mediastinal Large B Cell Lymphoma (PMBCL)\n  * Transformation Follicular Lymphoma (TFL)\n  * High grade B-cell lymphoma(HGBCL)\n  * High grade B-cell lymphoma (HGBCL) with MYC(myelocytomatosis oncogene) and BCL2(B-cell lymphoma2) \u002FBCL6 (B-cell lymphoma6) rearrangement\n* Refractory diseases are defined as one of the following\n\n  * No response to last line of therapy: i. Progressive disease (PD) as best response to most recent therapy regimen; ii. Stable disease (SD) as best response to most recent therapy regimen\n  * Not candidate for autologous stem cell transplant (ASCT) or refractory post-ASCT: i. Disease progression (PD) or relapsed ≤12 months of ASCT (must have biopsy proven recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy\n* Individuals must have received adequate prior therapy including at a minimum:\n\n  * anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative and\n  * an anthracycline containing chemotherapy regimen\n* Immunohistochemical staining shows at least two of B cell surface receptor antigen CD19,CD20, BCMA are positive(including weak, medium and strong positive)\n* At least one measurable lesion during the screening based on the recommendation for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma.\n* Life expectancy ≥ 12 weeks\n* Eastern cooperative oncology group (ECOG) performance status of 0 or 1\n* Adequate renal, hepatic, pulmonary and cardiac function defined as:\n\n  * Renal function: Serum creatinine ≤ 1.5 upper limit of normal(ULN), or eGFR ≥ 60 mL\u002Fmin\u002F1.73m2 \\[eGFR(estimated glomerular filtration rate)=186×age\\^-0.203×SCr\\^-1.154（mg\u002Fdl）,female×0.742\\]\n  * Hepatic function: i: Serum alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) ≤ 5 ULN and ii: total bilirubin ≤ 2 ULN, except in individuals with Gilbert syndrome (in Gilbert's syndrome patients, those with total bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN can be enrolled).iii: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN Pulmonary: Have the minimum level of pulmonary reserve, defined as ≤ CTCAE (Common Terminology Criteria for Adverse Events) grade 1 dyspnea and the SaO2(oxygen saturation)≥ 91% on room air\n  * Cardiac: left ventricular ejection fraction (LVEF) ≥50% determined by echocardiogram(ECG) or multigated acquisition scan (MUGA)\n* Adequate bone marrow function, define as:\n\n  * absolute neutrophil count (ANC) ≥1 ×10\\^9\u002FL\n  * absolute lymphocyte count (ALC)≥ 0.5 ×10\\^9\u002FL\n  * Platelets ≥50 ×109\u002FL；\n  * Hemoglobulin ≥80 g\u002FL; patients with bone marrow involvement can be enrolled if globulin\\>60 g\u002FL\n* Female of child-bearing age and male participants must agree to use effective contraceptive methods until no CAR-T cells can be detected by PCR(polymerase chain reaction) test.\n\nKey Exclusion Criteria:\n\n* Individuals who have antiCD45 or antiCD3 therapy\n* Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of primary or secondary CNS (central nervous system) lymphoma, cerebrospinal fluid malignant cells or brain metastases\n* Presence or history of CNS disorder such as seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n* History of allogeneic stem cell transplantation\n* Any of the following situations:\n\n  • HBsAg\u002F HBeAg positive; HBeAb\u002FHBcAb positive and HBV(hepatitis B virus) DNA copies above the lower test limit;\n* HCV(hepatitis C virus) RNA positive\n* HIV(human immunodeficiency virus) positive or treponema pallidum positive\n* Presence of active or life-threatening fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.\n* Individuals presence of unstable angina or myocardial infarction within 6 months of screening, or other severe\u002Funcontrolled diseases during the screening (eg. Unstable or uncompensated respiratory, cardiac, hepatic or renal disease)\n* Presence of uncontrolled arrhythmia with treatment\n* Pregnancy or breastfeeding women\n\nOther protocol defined inclusion\u002Fexclusion criteria may apply.",{"count":51,"type":21},[53],"This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19\u002FCD22\u002FBCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.",[109],"Non-Hodgkin Lymphoma, B-cell",[111,64,112,113,114],"B cell non-hodgkin lymphoma","CD19","CD22","BCMA","2025-08-19",{"date":90,"type":33},{"date":118,"type":33},"2024-05-07",{"date":96,"type":21},{"name":39,"class":40},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":41},"100572358","early-phase-1-a-dose-escalating-study-of-cd19cd22bcma-car-t-therapy-in-relapsed-refractory-multiple-myeloma-100572358","NCT06732232","A Dose Escalating Study of CD19\u002FCD22\u002FBCMA CAR-T Therapy in Relapsed\u002F Refractory Multiple Myeloma","A Dose Escalating Study of CD19\u002FCD22\u002FBCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Participants must meet all of the following criteria in order to be enrolled:\n\n  1. Understand and voluntarily sign an informed consent form (ICF) before conducting any research related evaluations\u002Fprocedures;\n  2. Age range: 18-75 years old;\n  3. Expected survival period is not less than 12 weeks;\n  4. ECOG score ≤ 2 points;\n  5. The bone marrow flow cytometry results showed positive BCMA antigen (including weak positive, moderate positive, and strong positive);\n  6. According to the IMWG criteria, a diagnosis of multiple myeloma with measurable lesions must meet at least one of the following criteria:\n\n     1. Serum M protein (SPEP) ≥ 5g\u002FL\n     2. 24-hour urinary M-protein excretion rate ≥ 0.2g (200mg)\n     3. Serum free light chain (sFLC) ≥ 100 mg\u002FL and abnormal free light chain ratio\n     4. The ratio of primitive plasma cells to immature plasma cells in bone marrow cytology examination is greater than 5%, or the flow cytometry detection of monoclonal plasma cells is greater than 5%\n  7. Those who have received treatment with at least three different mechanisms of action (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed, and have experienced relapse (within 12 months), difficulty in treatment, or intolerance to the last line treatment regimen, including primary difficulty in treatment (subjects who have not achieved minimal remission \\[MR\\] or developed disease progression \\[PD\\] during treatment) or secondary difficulty in treatment (subjects who develop disease progression within 60 days after completion of treatment);\n  8. There is no significant abnormality in lung function, and the oxygen saturation is greater than 92% in the absence of oxygen inhalation;\n  9. The blood biochemistry test results meet the following criteria:\n\n     1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)\n     2. Total bilirubin ≤ 1.5 × ULN\n     3. 24-hour serum creatinine clearance rate ≥ 30 mL\u002Fmin\n     4. Lipase and amylase ≤ 2 × ULN\n  10. The blood routine test meets the following criteria:\n\n      1. Lymphocyte count\\>0.5 × 10 \\^ 9\u002FL\n      2. Neutrophil count ≥ 1.0 × 10 \\^ 9\u002FL\n      3. Hemoglobin ≥ 60g\u002FL\n      4. Platelets ≥ 40 × 10 \\^ 9\u002FL\n  11. Men with fertility and women of childbearing age must agree to use effective contraceptive measures from the signing of the informed consent form until 2 years after the use of the study drug. Women of childbearing age include premenopausal women and women within 2 years after menopause. The blood pregnancy test for women of childbearing age must be negative during screening.\n\nExclusion Criteria:\n\n* Any of the following situations cannot be selected as a subject:\n\n  1. Asymptomatic (smoking type) multiple myeloma;\n  2. Multiple myeloma with only extramedullary lesions present;\n  3. Plasma cell leukemia;\n  4. Merge amyloidosis;\n  5. Central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic central compression;\n  6. Pregnancy or lactation period;\n  7. Individuals who are HBsAg positive or HBcAb positive, unless HBV-DNA is less than 100 IU\u002Fml or below the minimum detectable value; Individuals who are positive for hepatitis C virus (HCV) antibodies and HCV-RNA; Individuals who are HIV antibody positive; Individuals who are positive for syphilis specific antibodies and have a positive TRUST (toluidine red unheated serum test) test; Individuals who test positive for Cytomegalovirus (CMV) DNA;\n  8. Cardiovascular diseases with clinical significance, including any of the following:\n\n     1. QT interval (QTcF) after heart rate correction:\\>470 milliseconds;\n     2. New York Heart Association Grade II and above heart failure;\n     3. Left ventricular ejection fraction (LVEF) ≤ 50%;\n     4. Poorly controlled hypertension (systolic blood pressure ≥ 150 mm Hg and\u002For diastolic blood pressure ≥ 95 mm Hg)\n     5. Arrhythmias that have clinical significance or require antiarrhythmic treatment (such as persistent ventricular tachycardia, ventricular fibrillation, apical torsion tachycardia, and complete left bundle branch block);\n  9. Has experienced unstable angina or acute myocardial infarction within the 6 months prior to signing the ICF;\n  10. Previously received any anti-CD45 or anti-CD3 treatment;\n  11. Individuals who are allergic to any of the components of the drugs used in this study, including but not limited to Qing Lin drugs (cyclophosphamide, fludarabine), etc;\n  12. Received any investigational drug or systemic anti-tumor treatment within 4 weeks (or 5 half lives of the drug, whichever the researcher deems more appropriate) prior to single collection;\n  13. History of other primary malignant tumors within 5 years prior to treatment, except for the following situations:\n\n      1. Fully treat cured cervical carcinoma in situ;\n      2. Localized basal cell carcinoma or squamous cell carcinoma of the skin;\n  14. Any uncontrolled active infection within 4 weeks prior to single collection requires parenteral antibiotics, antiviral or antifungal treatment;\n  15. Individuals with a history of active pulmonary tuberculosis infection within one year prior to single sampling (excluding subjects with a history of active pulmonary tuberculosis infection more than one year ago who, according to the researcher's judgment, currently have no evidence of active pulmonary tuberculosis);\n  16. Accompanying or having a history of interstitial lung disease or interstitial pneumonia;\n  17. Subjects who receive autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of signing the ICF, or who plan to undergo ASCT during the study period;\n  18. Subjects who have received allogeneic stem cell therapy in the past; The researchers believe that complications or other conditions in the subjects may affect their compliance with the protocol or make them unsuitable to participate in this study.","75 Years",{"count":81,"type":21},[53],"This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19\u002FCD22\u002FBCMA in patients with relapsed\u002Frefractory multiple myeloma.",[133,134,135],"Relapsed","Refractory","Multiple Myeloma",[137,64,112,113,114],"relapsed\u002Frefractory multiple myeloma","2024-12-11",{"date":140,"type":33},"2024-12-13",{"date":142,"type":33},"2024-12-12",{"date":144,"type":21},"2027-12-12",{"name":39,"class":40},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100541295","early-phase-1-an-exploratory-study-by-fast-car-t-cells-100541295","NCT06327997","An Exploratory Study by Fast CAR T Cells","Exploratory Study on the Treatment of Advanced Solid Tumor With Non-viral Vector Multi-targeted Autosecretory Multifunctional Antibody CAR-T Cell Injection","Inclusion Criteria:\n\n* Patients diagnosed with advanced solid tumors through histopathological diagnosis have a positive rate of ≥ 50% for mesothelin expression membrane and ≥ 50% for MUC1 expression in tumor tissue samples. PD-L1 expression is positive, and the sample source is within 2 years；\n* Late stage malignant solid tumor patients who have failed standard treatment or are intolerant to such treatment and do not have a standard effective treatment plan ；\n* Greater than or equal to 18 years of age and less than or equal to 70 years of age on day of signing informed consent；\n* Life expectancy \\>3 months；\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；\n* Satisfactory organ and bone marrow function as defined by the following：\n\n  1. absolute neutrophil count must be greater than ≥ 1.5×10\\^9\u002FL, lymphocyte count must be greater than ≥ 0.5×10\\^9\u002FL, platelets must be greater than ≥ 90×10\\^9\u002FL, hemoglobin must be greater than ≥ 90g\u002FL without transfusion within 7 days or dependency on EPO;\n  2. Total bilirubin must be less than or equal to two times (≤2.0x) the institutional normal upper limit; transaminases, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), must be less than or equal to 2.5 times (≤2.5x) the institutional normal upper limit (≤5x if there is hepatic metastasis);\n  3. International normalized ratio (INR) or the PT is not greater than one and one half times (≤ 1.5) the upper limit of normal;\n  4. Lung function: ≤ CTCAE grade 1 dyspnea and SaO2≥ 91%；\n  5. Cardiac function: cardiac ejection fraction (LVEF) must be greater than fifty percent (≥50%) by echocardiogram or MUGA one month before enrollment.\n* Subjects must have measureable disease as defined by RECIST 1.1 criteria;\n* Subjects sufficiently understand the trial and willingly sign the informed consent；\n* Male and Female subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for at least 12 months following the last dose of the study cell infusion and until no CAR-T cells can be detected after two consecutive PCR tests.\n\nExclusion Criteria:\n\n* Subjects who have undergone other anti-tumor treatments (including radiation therapy, chemotherapy, small molecule, biological or immunotherapy, and other study drugs) other than lymphocytes depletion allowed by the protocol within one month prior to CAR-T infusion;\n* Prior therapy with any gene therapy (including CAR-T cell therapy) or any T cell therapy home and abroad;\n* Pregnant or breastfeeding women;\n* Positive serological reactions for HIV and syphilis; Hepatitis B surface antigen positive, hepatitis B core antibody positive, and hepatitis B virus DNA copy number higher than the detection limit and\u002For greater than or equal to 1000 copies\u002FmL; Or Hepatitis C virus infected individuals;\n* Any uncontrollable active infection, coagulation disorders, or any other major illness;\n* Patients with autoimmune diseases, organ transplantation and other immune related diseases under treatment, or long-term use of immunosuppressive drugs such as glucocorticoids: a. Glucocorticoids: users cannot stop using CAR-T cells 72 hours before infusion; b. Immunosuppressants other than glucocorticoids cannot be stopped ≥ 4 weeks before enrollment;\n* History of severe cardiac or pulmonary disease, including hypertension that cannot be controlled by medication, and any of the conditions occurred within the past 6 months: congestive heart failure (New York Heart Association functional classification ≥3), cardiac angioplasty and stents, myocardial infarction, unstable angina, or other clinically significant heart disease;\n* Detectable clinically relevant central nervous system (CNS) metastases and\u002For pathology such as epilepsy\u002Fseizure, brain Ischemia\u002F hemorrhage, dementia, cerebellar disease, or autoimmune disease affecting central nervous system.\n* Patients at high risk of causing bleeding or perforation;\n* Patients who had undergone major surgical procedures or significant trauma within 4 weeks before apheresis, or who were expected to require major surgery during the study period;\n* Patient has a known history of a hematologic malignancy, or of another malignant primary solid tumor concurrently, with the exception of :Patients with in situ cervical cancer or breast cancer with no evidence of disease for ≥ 3 years after curative treatments;Patients who underwent successful definitive resection of in situ cancer with no evidence of disease for ≥5 years;\n* Other circumstances that were deemed by the investigator to be inappropriate for trial participation.",{"count":51,"type":21},[53],"The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were infused on day 0 (the dose was determined according to the requirements of climbing\u002Fexpansion). The safety intensive observation period was 28 days after infusion, and the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation and evaluation were carried out according to the follow-up visit point, and the follow-up period was 1 year. From the second year, the telephone follow-up period was entered.",[157],"Solid Tumor","2024-03-18",{"date":160,"type":33},"2024-03-25",{"date":162,"type":33},"2024-03-07",{"date":164,"type":21},"2027-12-31",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":183,"locationsCount":41},"100535197","early-phase-1-exploratory-study-of-msln-car-t-cells-secreting-pd1ctla-4-nanoantibody-for-the-treatment-of-advanced-solid-tumors-100535197","NCT06248697","Exploratory Study of MSLN-CAR T Cells Secreting PD1\u002FCTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n* Patients must have a histological or cytological diagnosis of advanced solid tumors, such as non-small-cell lung cancer and mesothelioma；\n* Patients must have failed established standard medical anti-cancer therapies；\n* Greater than or equal to 18 years of age and less than or equal to 70 years of age on day of signing informed consent；\n* Life expectancy ≥3 months；\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；\n* Staining of MSLN must be greater than 50% of the cells in the tumor tissue and with apparent expression in the membrane. PD-L1 expression must be positive. Tissue obtained for the biopsy must be ≤3 year prior to enrollment for screening；\n* Satisfactory organ and bone marrow function as defined by the following:\n\n  1. Adequate bone marrow function in the opinion of the Investigator for lymphocyte-depleting chemotherapy: absolute neutrophil count must be greater than ≥ 1.5×10\\^9\u002FL, lymphocyte count must be greater than ≥ 0.5×10\\^9\u002FL, platelets must be greater than ≥ 90×10\\^9\u002FL, hemoglobin must be greater than ≥ 90g\u002FL without transfusion within 7 days or dependency on EPO;\n  2. Total bilirubin must be less than or equal to two times (≤2.0x) the institutional normal upper limit; transaminases, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), must be less than or equal to 2.5 times (≤2.5x) the institutional normal upper limit (≤2.5x if there is hepatic metastasis);\n  3. Creatinine must be less than or equal to one and one half times (≤ 1.5x) the institutional normal upper limit or eGFR ≥ 60ml\u002Fmin\u002F1.73m\\^2 \\[eGFR=186×（age）-0.203×SCr-1.154（mg\u002Fdl）,for female the eGFR shoud be timed by 0.742\\];\n  4. International normalized ratio (INR) or the PT is not greater than one and one half times (≤ 1.5) the upper limit of normal;\n  5. Lung function: ≤ CTCAE grade 1 dyspnea and SaO2≥ 91%;\n  6. Cardiac function: cardiac ejection fraction (LVEF) must be greater than fifty percent (≥50%) by echocardiogram or MUGA one month before enrollment.\n* Subjects must have measureable disease as defined by RECIST 1.1 criteria;\n* Subjects sufficiently understand the trial and willingly sign the informed consent;\n* Male and Female subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for at least 12 months following the last dose of the study cell infusion and until no CAR-T cells can be detected after two consecutive PCR tests.\n\nExclusion Criteria:\n\n* Prior therapy with targeted therapy or cell therapy against MSLN；\n* Prior therapy with any gene therapy (including CAR-T cell therapy) or any T cell therapy home and abroad；\n* Active bacteria, viral or fungal infection, and not contained after anti-infective therapy (positive results in the blood ≤72 hours before infusion);\n* Patient is positive for Syphilis, Human Immunodeficiency Virus (HIV) , active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA (qualitative) is detected);\n* Patient has a medical condition such as autoimmune disease or organ transplantation that requires chronic systemic steroid therapy or requires any other form of immunosuppressive medication;\n* History of severe cardiac or pulmonary disease, including hypertension that cannot be controlled by medication, and any of the conditions occurred within the past 6 months: congestive heart failure (New York Heart Association functional classification ≥3), cardiac angioplasty and stents, myocardial infarction, unstable angina, or other clinically significant heart disease；\n* Detectable clinically relevant central nervous system (CNS) metastases and\u002For pathology such as epilepsy\u002Fseizure, brain Ischemia\u002F hemorrhage, dementia, cerebellar disease, or autoimmune disease affecting central nervous system；\n* Patient has a history or current evidence of any condition such as neurotic, psychiatric, immune, metabolic and infectious disease, on any therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator；\n* Patient has a known history of a hematologic malignancy, or of another malignant primary solid tumor concurrently, with the exception of :\n\n  1. Patients with in situ cervical cancer or breast cancer with no evidence of disease for ≥ 3 years after curative treatments;\n  2. Patients who underwent successful definitive resection of in situ cancer with no evidence of disease for ≥5 years;\n* Has had chemotherapy, radioactive, small molecules, biological cancer therapy, immunotherapy or other investigational drugs within 2 weeks prior to the initiation of the study；\n* Pregnant or breastfeeding women;\n* Investigators think that patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study and cooperation with the requirements of the trial, uncontrolled medical, psychological, familial, sociological, or geographical conditions, or is not in the best interest of the patient to participate.",{"count":173,"type":21},16,[53],"This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 and CTLA-4 nanobodies (αPD1\u002FCTLA-4-MSLN-CAR T cells) in patients with solid tumors.",[157],"2024-02-07",{"date":179,"type":33},"2024-02-08",{"date":181,"type":33},"2023-01-01",{"date":96,"type":21},{"name":39,"class":40},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":41},"100535240","early-phase-1-an-exploratory-study-on-the-treatment-of-advanced-solid-tumors-by-fast-car-t-cells-100535240","NCT06249256","An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells","An Exploratory Study on the Treatment of Advanced Solid Tumors by Secretory PD1 Nanoantibody Targeting Mesothelin Fast CAR T Cells","Inclusion Criteria:\n\n* Patients diagnosed with advanced solid tumors through histopathological diagnosis have a positive rate of ≥ 50% for mesothelin expression membrane in tumor tissue samples, PD-L1 positive expression, and sample sources within 2 years；\n* Late stage malignant solid tumor patients who have failed standard treatment or are intolerant to such treatment and do not have a standard effective treatment plan；\n* Greater than or equal to 18 years of age and less than or equal to 70 years of age on day of signing informed consent；\n* Life expectancy \\>3 months；\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；\n* Satisfactory organ and bone marrow function as defined by the following:\n\n  1. absolute neutrophil count must be greater than ≥ 1.5×109\u002FL, lymphocyte count must be greater than ≥ 0.5×109\u002FL, platelets must be greater than ≥ 90×109\u002FL, hemoglobin must be greater than ≥ 90g\u002FL without transfusion within 7 days or dependency on EPO;\n  2. Total bilirubin must be less than or equal to two times (≤2.0x) the institutional normal upper limit; transaminases, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), must be less than or equal to 2.5 times (≤2.5x) the institutional normal upper limit (≤5x if there is hepatic metastasis);\n  3. International normalized ratio (INR) or the PT is not greater than one and one half times (≤ 1.5) the upper limit of normal;\n  4. Lung function: ≤ CTCAE grade 1 dyspnea and SaO2≥ 91%\n  5. Cardiac function: cardiac ejection fraction (LVEF) must be greater than fifty percent (≥50%) by echocardiogram or MUGA one month before enrollment.\n* Subjects must have measureable disease as defined by RECIST 1.1 criteria;\n* Subjects sufficiently understand the trial and willingly sign the informed consent；\n* Male and Female subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for at least 12 months following the last dose of the study cell infusion and until no CAR-T cells can be detected after two consecutive PCR tests.\n\nExclusion Criteria:\n\n* Subjects who have undergone other anti-tumor treatments (including radiation therapy, chemotherapy, small molecule, biological or immunotherapy, and other study drugs) other than lymphocytes depletion allowed by the protocol within one month prior to CAR-T infusion;\n* Prior therapy with any gene therapy (including CAR-T cell therapy) or any T cell therapy home and abroad;\n* Pregnant or breastfeeding women;\n* Positive serological reactions for HIV and syphilis; Hepatitis B surface antigen positive, hepatitis B core antibody positive, and hepatitis B virus DNA copy number higher than the detection limit and\u002For greater than or equal to 1000 copies\u002FmL; Or Hepatitis C virus infected individuals;\n* Any uncontrollable active infection, coagulation disorders, or any other major illness;\n* Patients with autoimmune diseases, organ transplantation and other immune related diseases under treatment, or long-term use of immunosuppressive drugs such as glucocorticoids: a. Glucocorticoids: users cannot stop using CAR-T cells 72 hours before infusion; b. Immunosuppressants other than glucocorticoids cannot be stopped ≥ 4 weeks before enrollment;\n* Patients who are allergic to BZT2312 components;\n* History of severe cardiac or pulmonary disease, including hypertension that cannot be controlled by medication, and any of the conditions occurred within the past 6 months: congestive heart failure (New York Heart Association functional classification ≥3), cardiac angioplasty and stents, myocardial infarction, unstable angina, or other clinically significant heart disease;\n* Detectable clinically relevant central nervous system (CNS) metastases and\u002For pathology such as epilepsy\u002Fseizure, brain Ischemia\u002F hemorrhage, dementia, cerebellar disease, or autoimmune disease affecting central nervous system\n* Patients at high risk of causing bleeding or perforation;\n* Patients who had undergone major surgical procedures or significant trauma within 4 weeks before apheresis, or who were expected to require major surgery during the study period;\n* Patient has a known history of a hematologic malignancy, or of another malignant primary solid tumor concurrently, with the exception of :Patients with in situ cervical cancer or breast cancer with no evidence of disease for ≥ 3 years after curative treatments;Patients who underwent successful definitive resection of in situ cancer with no evidence of disease for ≥5 years;\n* Other circumstances that were deemed by the investigator to be inappropriate for trial participation.",{"count":81,"type":21},[53],"This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of fast autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies in patients with solid tumors.",[157],{"date":179,"type":33},{"date":197,"type":33},"2023-06-01",{"date":96,"type":21},{"name":39,"class":40},""]